Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltest

    Forlagets udgivne version, 518 KB, PDF-dokument

  • T. Deis
  • E. Wolsk
  • Mujkanovic, Jasmin
  • J. Komtebedde
  • D. Burkhoff
  • D. Kaye
  • G. Hasenfuß
  • C. Hayward
  • J. Van der Heyden
  • M. C. Petrie
  • S. J. Shah
  • B. A. Borlaug
  • R. Kahwash
  • S. Litwin
  • E. Hoendermis
  • S. Hummel
  • Gustafsson, Finn

Aims: This study aimed to describe haemodynamic features of patients with advanced heart failure with preserved ejection fraction (HFpEF) as defined by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Methods and results: We used pooled data from two dedicated HFpEF studies with invasive exercise haemodynamic protocols, the REDUCE LAP-HF (Reduce Elevated Left Atrial Pressure in Patients with Heart Failure) trial and the REDUCE LAP-HF I trial, and categorized patients according to advanced heart failure (AdHF) criteria. The well-characterized HFpEF patients were considered advanced if they had persistent New York Heart Association classification of III–IV and heart failure (HF) hospitalization < 12 months and a 6 min walk test distance < 300 m. Twenty-four (22%) out of 108 patients met the AdHF criteria. On evaluation, clinical characteristics and resting haemodynamics were not different in the two groups. Patients with AdHF had lower work capacity compared with non-advanced patients (35 ± 16 vs. 45 ± 18 W, P = 0.021). Workload-corrected pulmonary capillary wedge pressure normalized to body weight (PCWL) was higher in AdHF patients compared with non-advanced (112 ± 55 vs. 86 ± 49 mmHg/W/kg, P = 0.04). Further, AdHF patients had a smaller increase in cardiac index during exercise (1.1 ± 0.7 vs. 1.6 ± 0.9 L/min/m2, P = 0.028). Conclusions: A significantly higher PCWL and lower cardiac index reserve during exercise were observed in AdHF patients compared with non-advanced. These differences were not apparent at rest. Therapies targeting the haemodynamic compromise associated with advanced HFpEF are needed.

OriginalsprogEngelsk
TidsskriftE S C Heart Failure
Vol/bind9
Udgave nummer1
Sider (fra-til)186-195
Antal sider10
ISSN2055-5822
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
F.G. has received research grants from the Novo Nordisk Foundation (NNF 20OC0060561) and honoraria from Abbott, Pfizer, Amgen, Bayer, Boehringer‐Ingelheim, Pharmacosmos, Alnylam, Novartis, Astra‐Zeneca, and Orion Pharma. J.K. is an employee of Corvia. S.J.S. has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapies, Bayer, Boehringer‐Ingelheim, Bristol‐Myers Squibb, Cardiora, CVRx, Cytokinetics, Eidos, Eisai, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Sanofi, Shifamed, Tenax, and United Therapeutics.

Publisher Copyright:
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

ID: 346051254